Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer (MITO CERV 3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04238988
Recruitment Status : Recruiting
First Posted : January 23, 2020
Last Update Posted : August 27, 2021
Sponsor:
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Brief Summary:
Single arm multicenter phase II trial evaluating the role of Pembrolizumab in combination to Carboplatin-Paclitaxel chemotherapy in locally advanced cervical cancer patients.

Condition or disease Intervention/treatment Phase
Locally Advanced Cervical Cancer Drug: Pembrolizumab Drug: Carboplatin Drug: Taxol Phase 2

Detailed Description:

Patients with stage IB2-IIB cervical cancer will be treated with 3 cycles of neoadjuvant Carboplatin-Paclitaxel chemotherapy (Carboplatin AUC 5 d1 q 21+ Paclitaxel 175 mg/mq d1 q 21)+ Pembrolizumab (200 mg flat dose every 3 weeks).

After 3 cycles of neo-adjuvant platinum-based chemotherapy patients non progressing will undergo radical surgery.

After surgery, patients presenting with high risk factors (positive lymphnodes, positive parametria, positive surgical margins or at least 2 of the following risk factor between tumor diameter >3 cm, LVSI, stromal infiltration >1/3) will receive 3 cycles of adjuvant Carboplatin-Paclitaxel chemotherapy + Pembrolizumab in combination and maintenance with Pembrolizumab 200 mg every 3 weeks until progression or unacceptable toxicity or patient consent withdrawal for up to 35 cycles.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single arm multicenter phase II trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study on Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
Actual Study Start Date : February 18, 2021
Estimated Primary Completion Date : September 1, 2023
Estimated Study Completion Date : September 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer

Arm Intervention/treatment
Experimental: Carboplatin-Paclitaxel-Pembrolizumab

Patients will be treated with 3 cycles of neoadjuvant Carboplatin-Paclitaxel chemotherapy (Carboplatin AUC 5 d1 q 21+ Paclitaxel 175 mg/mq d1 q 21)+ Pembrolizumab (200 mg flat dose every 3 weeks).

After 3 cycles of neo-adjuvant platinum-based chemotherapy patients non progressing will undergo radical surgery.

After surgery, patients presenting with high risk factors will receive 3 cycles of adjuvant Carboplatin-Paclitaxel chemotherapy + Pembrolizumab in combination and maintenance with Pembrolizumab 200 mg every 3 weeks until progression or unacceptable toxicity or patient consent withdrawal for up to 35 cycles.

Drug: Pembrolizumab
Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
Other Name: Keytruda

Drug: Carboplatin
Chemotherapy medication

Drug: Taxol
Chemotherapy medication
Other Name: Paclitaxel




Primary Outcome Measures :
  1. 2-years Progression-free survival [ Time Frame: 42 months ]
    The combination of Pembrolizumab-chemotherapy is expected to increase 2-years progression free survival with respect to historical controls.


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 42 months ]
    The combination of pembrolizumab- chemotherapy is expected to increase overall survival with respect to historical controls

  2. Clinical Response rate [ Time Frame: 42 months ]
    The combination of pembrolizumab-chemotherapy is expected to increase clinical response rate with respect to historical controls

  3. Pathologic optimal response [ Time Frame: 42 months ]
    The combination of pembrolizumab-chemotherapy is expected to increase pathologic response rate with respect to historical controls

  4. Adverse events [ Time Frame: 42 months ]
    The combination of pembrolizumab-chemotherapy is expected to have an acceptable toxicity profile

  5. Quality of life [ Time Frame: 42 months ]
    At baseline, every 3 cycles during the chemotherapy treatment phase, at chemotherapy completion, 6 months after chemotherapy completion, 1 and 2 years after chemotherapy completion and at progression, will be assessed the quality of life of patients according to the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and CX24. The questionnaires record in a scale from 1 (better outcome) to 4 (worse outcome) the physical, role, emotional, cognitive and social function of patients.

  6. Immune-related gene signatures associated with response or resistance to immune checkpoint blockade [ Time Frame: 42 months ]
    1)Messenger RNA (mRNA) transcript profiling will be performed.

  7. Immune-related gene signatures associated with response or resistance to immune checkpoint blockade [ Time Frame: 42 months ]
    blood sample will be collected before cycle 1, before cycle 6 and at progression. CD3 cells will be isolated and CD4/CD8 ratio will be evaluated by FACS analyses.

  8. Immune-related gene signatures associated with response or resistance to immune checkpoint blockade [ Time Frame: 42 months ]
    serum levels of IL -2, IL-10; TGF- Beta and IL-6 will be assessed.

  9. Immune-related gene signatures associated with response or resistance to immune checkpoint blockade [ Time Frame: 42 months ]
    tumor biopsies at progression will be collected in order to determine the PD-1R infiltrating lymphocyte population before and after treatment.

  10. Immune-related gene signatures associated with response or resistance to immune checkpoint blockade [ Time Frame: 42 months ]
    single and dual staining IHC analysis of: OX40-OX40L; ICOS; PD1, PD-L1, PD2, PDL2 and CTLA-4; FOXP3 and CD4; CD95 and CD95L



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of FIGO Stage IB2-IIB cervical cancer will be enrolled in this study. Squamous, adenocarcinoma and adenosquamous histotypes are admitted.
  2. PDL1+>1% of cell by IHC evaluation in tumor cells
  3. Eligible for carboplatin and paclitaxel chemotherapy in accordance with local standards of care
  4. A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR
    2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least 4 months after the end of treatment
  5. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
  6. Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  7. Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.

    Note: If submitting unstained cut slides, newly cut slides should be submitted to the testing laboratory within 14 days from the date slides are cut.

  8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the date of treatment initiation.
  9. Have adequate organ function as defined in the following table (Table 1). Specimens must be collected within 10 days prior to the start of study treatment.
  10. No previous systemic chemotherapy or radiation therapy for cervical cancer

Exclusion Criteria:

  1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment initiation (see Appendix 3). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
  3. Has received prior radiotherapy within 2 weeks of start of study treatment for palliative intent. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
  4. Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
  5. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.

    Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.

  6. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
  7. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
  8. Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
  9. Has severe hypersensitivity (≥Grade 3) to Pembrolizumab and/or any of its excipients.
  10. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  11. Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
  12. Has an active infection requiring systemic therapy.
  13. Has a known history of Human Immunodeficiency Virus (HIV).
  14. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection.
  15. Has a known history of active TB (Bacillus Tuberculosis).
  16. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  17. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  18. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.
  19. History of cerebrovascular accident, pulmonary embolism or untreated grade 3 deep venous thrombosis (DVT) within the past 6 months
  20. NCI CTCAE (version 5.0) grade ≥2 enteritis
  21. History of myocardial infarction, unstable angina, subarachnoid haemorrhage, stroke or transient ischaemic attack within 6 months before first dose of study drug
  22. Clinically significant active cardiovascular disease (e.g., New York Heart Association class II or greater congestive heart failure [CHF], aortic aneurysm)
  23. Serious cardiac arrhythmia requiring medication. This does not include asymptomatic atrial fibrillation with controlled ventricular rate
  24. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months before study enrolment
  25. Pre-existing NCI CTCAE (version 5.0) grade ≥2 peripheral neuropathy

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04238988


Contacts
Layout table for location contacts
Contact: Domnica Lorusso, MD 0630157337 ext +39 domenica.lorusso@policlinicogemelli.it
Contact: Serena Giolitto, MSc 0630158545 ext +39 serena.giolitto@policlinicogemelli.it

Locations
Layout table for location information
Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS Recruiting
Rome, Italy, 00168
Sponsors and Collaborators
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Merck Sharp & Dohme LLC
Layout table for additonal information
Responsible Party: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ClinicalTrials.gov Identifier: NCT04238988    
Other Study ID Numbers: 2586
First Posted: January 23, 2020    Key Record Dates
Last Update Posted: August 27, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Paclitaxel
Carboplatin
Pembrolizumab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological